Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: a follow-up study of an elderly cohort. 2015

Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

This study was to elucidate longitudinally quantitative changes of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA in elder HBsAg carriers in a community. Among 1002 residents screened for HBsAg in 2005, 405 responded to this follow-up study in 2010. Fifty-nine (14.6%) were HBsAg carriers in 2005; HBsAg quantification and HBV DNA were measured. HBsAg quantification (cutoff 1600 IU/mL) and HBV DNA (cutoff 2000 IU/mL) were combined to stratify the participants between two screens. A total of 30 men and 29 women with a mean age of 63.9 ± 7.9 years were enrolled. Quantitative levels of HBsAg and HBV DNA were significantly correlated in 2005 (r = 0.509, p < 0.001) and 2010 (r = 0.777, p < 0.001). Concentrations of HBsAg (IU/mL) significantly decreased from 2.2 ± 1.0 log in 2005 to 1.7 ± 1.5 log in 2010 (p < 0.001). The level of HBsAg was decreased in 48 (81.4%) individuals and HBsAg was undetectable in eight (13.6%). The annual incidence of HBsAg clearance was 2.7%. These 59 HBsAg carriers in 2005 were divided into four groups: low HBsAg low HBV DNA (n = 32), high HBsAg low HBV DNA (n = 5), low HBsAg high HBV DNA (n = 12) and high HBsAg high HBV DNA (n = 10). All 32 individuals in the low HBsAg low HBV DNA group were still in that group in 2010, whereas only two of the high HBsAg high HBV DNA group became inactive. As with a younger cohort in hospital, HBsAg quantification was still well correlated with HBV DNA in elderly HBsAg carriers in the community. Lower levels of both HBsAg and HBV DNA might represent an inactive HBV infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
July 2015, The Kaohsiung journal of medical sciences,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
November 2004, European journal of gastroenterology & hepatology,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
March 2015, Liver international : official journal of the International Association for the Study of the Liver,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
August 2004, Journal of medical virology,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
April 2018, Clinical laboratory,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
June 2010, Expert review of anti-infective therapy,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
January 2018, Annals of hepatology,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
June 2002, Gastroenterology,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
April 1994, Gastroenterology,
Yuan-Hung Kuo, and Kuo-Ching Chang, and Jing-Houng Wang, and Pei-Shan Tsai, and Shu-Feng Hung, and Chao-Hung Hung, and Sheng-Nan Lu
April 2014, Hepatology international,
Copied contents to your clipboard!